Platinum-containing drugs (eg, cisplatin) are among the most frequently used
chemotherapeutic agents. Their tremendous success has spurred research and …

In this review, we consider the main processes for the asymmetric transfer hydrogenation of
ketones from 2008 up today. The most effective organometallic compounds (derived from …

A new hydrogenation catalyst based on a manganese complex of a chiral P, N, N ligand has
been found to be especially active for the hydrogenation of esters down to 0.1 mol% catalyst …

Catalytic anticancer metallodrugs active at low doses could minimize side-effects, introduce
novel mechanisms of action that combat resistance and widen the spectrum of anticancer …

DFT calculations on the full catalytic cycle for manganese catalysed enantioselective
hydrogenation of a selection of ketones have been carried out at the PBE0‐D3PCM//RI …

Hydrogenation reactions in biology are usually carried out by enzymes with nicotinamide
adenine dinucleotide (NAD (P) H) or flavin mononucleotide (FAMH2)/flavinadenine …

With the aim to design water-soluble organometallic Ru (II) complexes acting as anticancer
agents catalyzing transfer hydrogenation (TH) reactions with biomolecules, we have …

We highlight recent developments of catalytic transfer hydrogenation of ketones promoted
by transition metals, while placing it within its historical context. Since optically active …

Most metallodrugs are prodrugs that can undergo ligand exchange and redox reactions in
biological media. Here we have investigated the cellular stability of the anticancer complex …

Anticancer agents that exhibit catalytic mechanisms of action offer a unique multi‐targeting
strategy to overcome drug resistance. Nonetheless, many in‐cell catalysts in development …